USP Comment Letter: Submitted to FDA on Clinical Immunogenicity Insulin Draft Guidance (2020)

Submitted on January 27, 2020 - USP Comment Letter on FDA’s draft guidance, “Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.” Docket No. FDA-2019-D-5255.